Gene Therapy & Genetic Medicine

Eli Lilly is using GLP-1 cash to buy genetic medicine

Lilly is the most active investor in the theme (6 deals), and it has moved from minority checks to outright acquisitions: Kelonia Therapeutics (in vivo CAR-T, up to $7B, April 2026) and Tune Therapeutics (epigenetic editing, Oct 14). It also sits in the cap table of a $120M Series B alongside a16z, Matrix and BoxGroup. Commentary in the signals frames Lilly as the first $1T healthcare company, with roughly $90B in GLP-1 revenue funding a shift toward corporate-led R&D. Genetic medicine is where that surplus is being deployed.

Kelonia's iGPS lentiviral particles, which reprogram T-cells inside the body with a one-time injection, validated the category with the Lilly deal. Vivacta Bio in Shanghai is chasing the same in vivo approach. Skipping ex vivo manufacturing is the central commercial promise.

Why it matters · Delivery chemistry and targeting, not the editing payload, are becoming the scarce assets that acquirers pay for.

Baby KJ, treated at Penn with a bespoke gene-editing therapy for a rare ammonia-processing disorder at a cost of $1.5M, is now walking and talking at age 2, and CHOP delivered the first personalized CRISPR therapeutic. Moderna and Merck's personalized mRNA melanoma vaccine cut recurrence by about 50% when paired with Keytruda. MB Therapeutics' French GMP cartridge approval points to hospital-pharmacy manufacturing as a way to standardize bespoke production.

Why it matters · Clinical proof for bespoke therapies creates openings for manufacturing and regulatory-infrastructure businesses as well as drug developers.

A $103M Series A backed by RA Capital, GV, Deep Track, Biogen New Ventures and UPMC Enterprises, plus a $37M Series A from Sound Bioventures and HealthCap and a $30M round with Amgen, F-Prime and GV, show early-stage rounds returning. Series A and Series B each had 10 deals over 90 days, though Series B carried $1.99B against $461M for Series A. Weekly capital reached $563M and $471M in the last two full weeks after a quiet September.

Why it matters · Large specialist-led first rounds indicate that investors are again willing to underwrite platform risk before clinical data exists.

Multiple IPOs were priced in October, including $200M, $184.7M, $133.3M and $116.7M raises, and one with Eli Lilly as an investor. Hemab's $301.5M US IPO, backed by Novo Holdings and RA Capital, is a rare-disease precedent. Shionogi's $2B IntraBio acquisition and Roche's $1.16B Rona deal add further exit options.

Why it matters · Public-market and M&A exits are visible again, which supports follow-on private financing.